AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25635970
Drug: Prophylactic oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic oral, rectal or vaginal misoprostol
Trial: 25635970
Drug: No-treatment option
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment option
Trial: 20567999
Drug: ZP-PTH 20
RxNorm normalized name: PTH
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ZP-PTH 20 µg
Trial: 20567999
Drug: ZP-PTH 30
RxNorm normalized name: PTH
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ZP-PTH 30 µg
Trial: 20567999
Drug: ZP-PTH 40
RxNorm normalized name: PTH
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ZP-PTH 40 µg
Trial: 20567999
Drug: FORTEO® injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FORTEO® injection
Trial: 16569219
Drug: scFOS 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: scFOS 2.5 g/d
Trial: 16569219
Drug: scFOS 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: scFOS 5 g/d
Trial: 16569219
Drug: scFOS 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: scFOS 7.5 g/d
Trial: 16569219
Drug: scFOS 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: scFOS 10 g/d
Trial: 16569219
Drug: scFOS (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: scFOS (all doses)
Trial: 16569219
Drug: scFOS 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: scFOS 2.5 g/d and 5 g/d
Trial: 12691651
Drug: Brånemark System
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brånemark System TiUnite surface implants
Trial: 12691651
Drug: Brånemark System
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brånemark System machined-surface implants
Trial: 11890519
Drug: Oral phentolamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral phentolamine (Vasomax) 40 mg before sleep
Trial: 9623694
Drug: Inspiratory flow
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory flow rate (V'I) at 30 L x min(‐1)
Trial: 9623694
Drug: Inspiratory flow
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory flow rate (V'I) at 60 L x min(‐1)
Trial: 9623694
Drug: Inspiratory flow
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory flow rate (V'I) at 90 L x min(‐1)
Trial: 9623694
Drug: Inspiratory flow
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory flow rate (V'I) changes from 30 to 90 L x min(‐1)
Trial: 27757553
Drug: Fosaprepitant 150
RxNorm normalized name: fosaprepitant 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosaprepitant 150 mg
Trial: 25500485
Drug: New twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New twice daily sustained-release (SR) paracetamol formulation (2 x 1,000 mg)
Trial: 25500485
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) paracetamol (2 x 500 mg)
Trial: 25500485
Drug: Extended-release (ER)
RxNorm normalized name: Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release (ER) paracetamol (2 x 665 mg)
Trial: 19904268
Drug: RT‐5‐FU arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT‐5‐FU arm (5-fluorouracil 350 mg m(‐2) per day during radiotherapy)
Trial: 19904268
Drug: RT‐GC arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT‐GC arm (gemcitabine 300 mg m(‐2) and cisplatin 30 mg m(‐2) on days 1, 8, 22, and 29)
Trial: 19904268
Drug: RT‐GC+GC arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT‐GC+GC arm (same concurrent treatment followed by sequential full-dose gemcitabine 1000 mg m(‐2) and cisplatin 50 mg m(‐2) every 2 weeks)
Trial: 15310642
Drug: Morphine PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine PCA plus a background infusion (group PCA-B)
Trial: 15310642
Drug: Morphine PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine PCA alone (group PCA-A)
Trial: 11123499
Drug: Paeoniae Radix
RxNorm normalized name: PAEONIA
DrugBank: Paeonia lactiflora root (DB16595)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paeoniae Radix (1.2 g extract powder once daily for 7 days) + 200 mg VPA on day 7
Trial: 11123499
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg VPA gastro-resistant tablet alone on day 7
Trial: 31738372
Drug: Minocycline 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline 400 mg/d
Trial: 19895780
Drug: Minocycline 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline 200 mg/d
Trial: 31738372
Drug: Combined Minocycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Minocycline (400 mg/d and 200 mg/d)
Trial: 31738372
Drug: Minocycline 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline 400 mg/d vs 200 mg/d
Trial: 24024532
Drug: Fluoxetine or
RxNorm normalized name: fluoxetine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine or Venlafaxine
Trial: 14641990
Drug: Gefitinib (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib (250 mg or 500 mg daily) in combination with carboplatin/paclitaxel
Trial: 14641990
Drug: Gefitinib (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib (250 mg or 500 mg daily) in combination with cisplatin/gemcitabine
Trial: 6336891
Drug: Orgotein (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orgotein (4 mg a week for six weeks)
Trial: 6336891
Drug: Methylprednisolone acetate
RxNorm normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone acetate (4 mg a week for six weeks)
Trial: 30617724
Drug: Sodium monensin
RxNorm normalized name: Monensin
DrugBank: Monensin (DB11430)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium monensin (MON; Rumensin® 200, Elanco Animal Health, Brazil) @ 0.6 mg/kg of body weight for 90 days
Trial: 30047502
Drug: Conventional evidence-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional evidence-based therapy
Trial: 21885990
Drug: Short-term statin
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term statin pretreatment (3-7 days) with atorvastatin (lipophilic statin)
Trial: 15365307
Drug: Naltrexone (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (titrated to 50 mg/day)
Trial: 15365307
Drug: Nalmefene (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalmefene (titrated to 40 mg/day)
Trial: 15365307
Drug: Alcohol (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.4 mg/kg for men, 0.34 mg/kg for women)
Trial: 17944734
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (maintenance CNI dose)
Trial: 17013995
Drug: Ibuprofen-arginine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen-arginine (400 mg)
Trial: 6360786
Drug: 10-micrograms doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-micrograms doses of 15-R-15 methyl prostaglandin E2 for 24 h before treatment with aspirin
Trial: 31120674
Drug: Vatinoxan (117-297
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vatinoxan (117-297 μg/kg)
Trial: 26069949
Drug: Trivalent Inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent Inactivated Influenza Vaccine (TIV)
Trial: 11844641
Drug: Glutamine (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine (80 mg/kg)
Trial: 9671862
Drug: Alfuzosin, 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin, 2.5 mg three times daily for 3 months, followed by maintenance of alfuzosin
Trial: 9671862
Drug: Alfuzosin, 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin, 2.5 mg three times daily for 3 months, followed by alfuzosin every other day
Trial: 9671862
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of alfuzosin (no treatment)
Trial: 28877729
Drug: Enhanced feedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced feedback (monthly written feedback incorporating goal setting and action planning delivered by a senior clinical coordinator)
Trial: 28877729
Drug: Standard feedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard feedback (2‐monthly written feedback on multiple quality of pediatric care indicators)
Trial: 27002696
Drug: Antiviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral therapy and surgical procedures
Trial: 27002696
Drug: Dental treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental treatment, local and systemic keratoplastic formulations
Trial: 20035590
Drug: Slow titration
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow titration schedule, 1.4 mg/kg/day
Trial: 20035590
Drug: Slow titration
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow titration schedule, 0.8 mg/kg/day
Trial: 20035590
Drug: Fast titration
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast titration schedule, 1.4 mg/kg/day
Trial: 20035590
Drug: Fast titration
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast titration schedule, 0.8 mg/kg/day
Trial: 20035590
Drug: Both maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both maintenance treatment groups (0.8 mg/kg/day and 1.4 mg/kg/day)
Trial: 15162466
Drug: IL-2Rab (basiliximab)
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-2Rab (basiliximab) 20 mg intravenously within 6 hours of graft reperfusion and on postoperative day 4
Trial: 15162466
Drug: Steroid group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid group (standard immunosuppressive regimen with tacrolimus and corticosteroid), n = 49
Trial: 8403178
Drug: Bupivacaine-lidocaine mixture,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine-lidocaine mixture, pH 6.7 with hyaluronidase (10 units.ml-1)
Trial: 6752875
Drug: Pirprofen 800
RxNorm normalized name: Carprofen
DrugBank: Carprofen (DB00821)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pirprofen 800 mg/day
Trial: 27785747
Drug: Chronic alkali
RxNorm normalized name: alkali blite pollen extract
DrugBank: Suaeda moquinii pollen (DB10953)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic alkali therapy
Trial: 27785747
Drug: No chronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No chronic alkali therapy
Trial: 12937009
Drug: Cefaclor (CFC)
RxNorm normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefaclor (CFC) 20 mg/kg
Trial: 12937009
Drug: Amoxicillin-clavulanic acid
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanic acid (AMX/CA) 20 mg/kg (4:1 ratio)
Trial: 10321661
Drug: Hydrocortisone (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (loading dose of 100 mg followed by continuous infusion of 0.18 mg/kg/hr, reduced to 0.08 mg/kg/hr after shock reversal)
Trial: 7577590
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 0.05% cream applied once-daily
Trial: 7577590
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 0.05% cream applied twice-daily
Trial: 7577590
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 0.05% cream applied once-daily with vehicle cream
Trial: 7577590
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 0.05% cream applied once-daily and twice-daily
Trial: 28109092
Drug: Preoperative mechanical
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative mechanical bowel preparation
Trial: 28109092
Drug: No preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preoperative mechanical bowel preparation
Trial: 19228431
Drug: 7-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-valent pneumococcal conjugate and booster 23-valent polysaccharide vaccine
Trial: 16511715
Drug: 0.5% isotonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% isotonic solution of sodium carboxymethylcellulose (CMC)
Trial: 24563419
Drug: Prescription medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription medications
Trial: 10731269
Drug: Intracoronary diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary diltiazem (1 mg)
Trial: 10731269
Drug: Intracoronary verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary verapamil (200 mcg)
Trial: 9492666
Drug: Adjuvant psychological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant psychological therapy
Trial: 31259608
Drug: Acetazolamide 125
RxNorm normalized name: acetazolamide 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide 125 mg twice daily, day of ascent dosing
Trial: 31259608
Drug: Acetazolamide 125
RxNorm normalized name: acetazolamide 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide 125 mg twice daily, night before dosing
Trial: 24512643
Drug: PSA levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA levels below 1 ng/ml
Trial: 19147527
Drug: Enoxaparin 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 1.5 mg/kg once daily
Trial: 19147527
Drug: Enoxaparin 1
RxNorm normalized name: ENOXAPARIN 100MG/ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 1 mg/kg twice daily (Control)
Trial: 17592287
Drug: Intermittent Sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent Sequential Pneumatic Compression (ISPC) device during pneumoperitoneum (PP)
Trial: 16146494
Drug: IFN-beta-1a 44
RxNorm normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IFN-beta-1a 44 microg subcutaneous three times weekly (t.i.w.) for 12 months
Trial: 16146494
Drug: Post-treatment follow-up
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment follow-up without IFN-beta-1a
Trial: 16146494
Drug: During treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During treatment and follow-up
Trial: 9784675
Drug: Outpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient treatment with low‐molecular‐weight heparin
Trial: 9784675
Drug: In-hospital treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-hospital treatment with unfractionated heparin
Trial: 7840824
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg i.v. of murine anti EGF‐R IgG2a mab EMD 55900
Trial: 7840824
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg i.v. of murine anti EGF‐R IgG2a mab EMD 55900
Trial: 7840824
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg i.v. of murine anti EGF‐R IgG2a mab EMD 55900
Trial: 7840824
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg i.v. of murine anti EGF‐R IgG2a mab EMD 55900
Trial: 3340118
Drug: 12 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 weeks of chemohormonal therapy (cyclophosphamide, methotrexate, fluorouracil, vincristine, prednisone, doxorubicin, tamoxifen)
Trial: 3340118
Drug: 36 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 36 weeks of chemotherapy (cyclophosphamide, methotrexate, fluorouracil, vincristine, prednisone)
Trial: 27575584
Drug: Whole‐body cold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole‐body cold mist shower therapy
Trial: 25611597
Drug: Typical, non‐standardized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typical, non‐standardized physiotherapy treatment (CG)
Trial: 18680695
Drug: Screened for
RxNorm normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screened for HLA‐B*5701 before starting abacavir treatment
Trial: 18680695
Drug: Epicutaneous patch
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epicutaneous patch testing for immunological confirmation
Trial: 17154749
Drug: Exposure-based treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure-based treatments
Trial: 10557020
Drug: Sibutramine 15
RxNorm normalized name: sibutramine 15 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine 15 mg daily for 12 weeks
Trial: 10557020
Drug: Sibutramine 15
RxNorm normalized name: sibutramine 15 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine 15 mg daily and Placebo
Trial: 8533749
Drug: Mass treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass treatment and behavior modification campaign
Trial: 8533749
Drug: Improved face-washing
RxNorm normalized name: Phisoderm Clear Confidence Daily Gel Face Wash
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improved face-washing plus antibiotic treatment
Trial: 1882473
Drug: Low Level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Level Laser therapy (Galium‐Aluminium‐Arsenide laser, 30 mW/830 nm, Unilaser 2000 3B)
Trial: 28116431
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C and compound vitamin B2, taken orally for 2 courses.
Trial: 20685507
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (generic glimepiride 2 mg)
Trial: 20685507
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (branded glimepiride 2 mg)
Trial: 18714738
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment consisting of a 7-day administration of one proton pump inhibitor and 2 out of 3 antibiotics (amoxicillin, clarithromycin, metronidazole)
Trial: 18714738
Drug: Quadruple treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple treatment regimen consisting of bismuth salts, tetracycline, metronidazole, and proton pump inhibitor
Trial: 18714738
Drug: New antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New antibiotics (levofloxacin and rifabutin) for Hp eradication
Trial: 18714738
Drug: Eradication treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eradication treatment assessed with urease or breath test
Trial: 12870120
Drug: Long-cycle structured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-cycle structured intermittent therapy (SIT; 4 weeks without HAART followed by 8 weeks with HAART)
Trial: 17972364
Drug: Continuous highly
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous highly active antiretroviral therapy (HAART)
Trial: 1777297
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment from general practitioner
Trial: 7048668
Drug: DEC (diethylcarbamazine)
RxNorm normalized name: Zodryl DEC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEC (diethylcarbamazine) given in spaced doses (once weekly, monthly, or bi-monthly)
Trial: 7048668
Drug: DEC (diethylcarbamazine)
RxNorm normalized name: Zodryl DEC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEC (diethylcarbamazine) at a total dose of 36-48 mg/kg
Trial: 7048668
Drug: DEC (diethylcarbamazine)
RxNorm normalized name: Zodryl DEC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEC (diethylcarbamazine) at a total dose of 72 mg/kg
Trial: 7048668
Drug: Levamisole (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole (3 mg/kg) prior to DEC (6 mg/kg/day for 7 days)
Trial: 7048668
Drug: Retreatment with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retreatment with DEC (6 mg/kg/day for 7 days)